HCPLive Editorial Staff

The 2022 scientific sessions in Louisville, Kentucky will emphasize inclusiveness and the care for all at risk for cardiovascular disease.

Dr. Jennifer Green led a panel in discussing new treatments and topics in diabetes care.

A group of experts discuss new and emerging therapies for IBD.

There are several emerging treatments for C difficile infections.

There is a need for new medications for depression to overcome high rates of treatment resistance.

Dr. Kenneth J. Warrington led the panel in discussing various topics in rheumatology.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

Dr. Serge Jabbour led the panel in discussing emerging treatments for type 2 diabetes.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

Those with a history of severe allergic reaction to vaccines are recommended to consider deferring on the recently approved COVID-19 vaccine.

Study data suggested that up to 80% of patients with Parkinson disease may have ophthalmologic symptoms.

The FDA has approved a quadrivalent formula of the adjuvanted seasonal influenza vaccine from Seqiris.